Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03604107 · ClinicalTrials.gov registry record
Predictive Value of Embryonic Testing
A clinical trial, sponsored by Reproductive Medicine Associates of New Jersey.
- Completed
- Registry status
- 237
- Enrollment target
NCT03604107: Completed study, sponsored by Reproductive Medicine Associates of New Jersey.
NCT03604107 is a clinical trial that has completed, run by Reproductive Medicine Associates of New Jersey. The registered enrollment target is 237 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03604107 has completed, sponsored by Reproductive Medicine Associates of New Jersey.
- COMPLETED
- Registry status
- 237 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the predictive value of preimplantation genetic screening (PGS) as a marker of embryonic competence. Secondary objectives are to define the related or independent predictive values of other proposed markers of embryonic and maternal reproductive competence in assisted reproductive technology (ART) cycles.
Primary Outcome
Determine confidence intervals that a euploid embryo will implant, an aneuploid embryo will not implant, and the likelihood of mosaic and segmental aneuploid embryos implanting and describe their outcomes.
Interventions
- GENETIC Preimplantation Genetic Testing-Aneuploidy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2018-07-30 |
| Est. Completion | 2020-12-01 |
What the finished NCT03604107 record still lists
NCT03604107 is an observational study that tracks outcomes without assigning an intervention. The registered 237 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Preimplantation Genetic Testing-Aneuploidy is the first listed.
NCT03604107 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03604107 about?
NCT03604107 is a clinical study titled "Predictive Value of Embryonic Testing". The primary objective of this study is to determine the predictive value of preimplantation genetic screening (PGS) as a marker of embryonic competence. Secondary objectives are to define the related or independent predictive values of other proposed markers of embryonic and maternal reproductive co...
What is the current status of trial NCT03604107?
This trial is currently completed. The enrollment target is 237 participants. The study started on 2018-07-30. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT03604107?
The interventions under investigation include: Preimplantation Genetic Testing-Aneuploidy (GENETIC).
Who is sponsoring clinical trial NCT03604107?
This trial is sponsored by Reproductive Medicine Associates of New Jersey, which has 51 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05974176 · 237 participants · NA
Considering Racial and Acculturation Stress in Addressing Trauma
- NCT05012072 · 238 participants · NA
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
- NCT05400252 · 238 participants · NA
Whole Health in VA Mental Health: Omnis Salutis
- NCT06380517 · 238 participants · Phase 3
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI